5-HT1F receptor
Assets acting on this target.
- Class
- Selective serotonin 5-HT1F receptor agonist (ditan)
Assets acting on this target.
1 of 1 assets (1 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| Lasmiditan (Reyvow) (Reyvow) | Eli Lilly | 5-HT1F receptor | Migraine | Ph 3 | FDA-approved for acute treatment of migraine, NDA211280 ORIG-1 approved 2019-10-11, the indication carried in the original label. APPROVED-BUT-DISCONTINUED: Drugs@FDA records all three REYVOW strengths (50/100/200 mg) as Discontinued; per the 2026-08-31 ruling the market stays approved with its date and the discontinuation is recorded here. | source ↗ |